SCHEMBL4940165

SCHEMBL4940165

CCCC(Br)C(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.62
SLC6A4 P31645 1/20 0.58
CES2 O00748 2/20 0.50
CES1 P23141 2/20 0.50
PTPN1 P18031 2/20 0.49
CYP3A4 P08684 2/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
SRD5A2 P31213 2/20 0.42
LMNA P02545 1/20 0.42
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
PDPK1 O15530 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9022367 0.85 GSK3B (0.64) GSK3BSLC6A4CES2CES1PTPN1
SCHEMBL19880762 0.82 SLC6A4 (0.59) GSK3BSLC6A4CES2CES1PTPN1
SCHEMBL27666336 0.82 SLC6A4 (0.59) GSK3BSLC6A4CES2CES1PTPN1
SCHEMBL19707606 0.82 TAS1R3 (0.61) CES2TAS1R3TAS1R1SRD5A2LMNA
SCHEMBL4936186 0.81 SLC6A3 (0.55) SLC6A4CES2CES1PTPN1
SCHEMBL4937398 0.80 SLC6A3 (0.54) GSK3BSLC6A4CES2CES1LMNA
SCHEMBL17644172 0.80 SLC6A2 (0.54) SLC6A4PTPN1CYP3A4LMNAPDPK1
SCHEMBL4935111 0.80 SLC6A3 (0.56) GSK3BSLC6A4CES2CES1MEN1
SCHEMBL5052384 0.79 GSK3B (0.64) GSK3BSLC6A4CES2CES1PTPN1
SCHEMBL4936099 0.78 GSK3B (0.58) GSK3BSLC6A4PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) 2008-09-25 US disclosed
EP-1670755-A4 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF HARVARD COLLEGE (US) 2007-02-28 EP disclosed
EP-1670755-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF President And Fellows of Harvard College (US) 2006-06-21 EP disclosed
WO-2005034878-A2 PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234498-A1 Pyrovalerone Analogues and Therapeutic Uses Thereof SLC6A2, SLC6A4, SLC6A3 GSK3B 539/4885SLC6A4 2/4885CES2 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.